Current Price{{movement}} ${{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{marketstatus.OPEN ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Agenix Limited (AGX)
is a publicly listed company on the Australian Securities Exchange (ASX).


General Overview

About Agenix Limited

AGXIn 1982, a small research group based at the Queensland Institute of Technology formed the nucleus of Queensland's first biotechnology company as a spin off from University research. The company was called MabCo and was situated in Springwood. The vision was to capitalise on the emerging field of monoclonal antibody diagnostics. The company listed on the Australian Stock Exchange in 1987 (ASX: AGX).

Success was rapid, resulting in AGEN being named Queensland Exporter of the Year for 1993. Today, AGENIX is a publicly listed, Australian based international biotechnology company. Its lead diagnostic test is a patented radio-labeled monoclonal antibody called Thromboview® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning Thromboview® as an innovative diagnostic (a 'theranostic') to support the use of developed biopharmaceuticals and is seeking a development partner to commercialise the indicator.



AGXThromboView® was created to meet the specific needs of medical professionals worldwide who need a better method to accurately and safely detect live blood clots and pulmonary embolisms without exposing patients to the high levels of radiation and toxic imaging chemicals currently used.

The global market for an accurate, effective and safe way to detect blood clots is independently estimated to be worth at least US$400 million per year. This is based on the growing annual number of deep vein thrombosis cases and tests at hospitals to detect pulmonary embolism.


Agenix is commercialising the proven rapid point-of-care diagnostic platform called DiagnostIQ for a range of human health applications. DiagnostIQ is used globally by Bayer Crop Science AG in agriculture to test for plant disease. DiagnostIQ enhances Agenix's human health diagnostics business and opens up multiple commercial licensing opportunities that will generate revenues and expand their Dx business.

DiagnostIQ's patented 'flo-thru' design will be further developed to allow multiple diagnostic tests to be undertaken simply and quickly on the one system. Agenix is open to licensing the platform to other healthcare businesses who already have the components for a human health test, but no viable point-of care testing platform.

They are also focused on developing licensing opportunities for DiagnostIQ in the world's emerging markets where access to laboratory instruments is limited. Intellectual property protection on DiagnostIQ extends to 2022, with extension of protection possible for individual tests. DiagnostIQ is an exciting addition to their business and builds on their core corporate strengths in human diagnostics and licensing.


Agen Biomedical

AGEN specialises in advanced medical diagnosis of human diseases and is well positioned as a world-class thrombosis and blood clot specialist. Building on existing technology platforms, AGEN is continuously investing in research and development. AGEN is in the process of commercialising a breakthrough technology in blood clot imaging called ThromboView®.

Agenix Biopharmaceutical

Agenix Biopharmaceutical (Shanghai) is a wholly owned Agenix Limited biopharmaceutical manufacturing organisation, headquartered in Shanghai, China. The company's lead product is a patented next generation prodrug of an anti-hepatitis B virus (HBV) drug, currently under pre-clinical development. The company also has rest-of-world rights to an anti HBV drug marketed in China as You He Ding which on 2 October 2007 received SFDA approval and market introduction in China. In China, YouHeDing is sold directly by its manufacturer and through Sinopharm, the largest medical products and pharmaceutical distributor in China.

Contact Info

Agenix Limited

Ground Floor
156 Collins Street
Melbourne, VIC
AU Australia, 3000

Phone: +61 4 6755 9037
Fax: +61 3 8616 0382

Click here to view the interactive map
Agenix Limited Google Map
Agenix Limited Google Map

Share Registry

Advanced Share Registry Services - Click here to view share registry profile

Phone: +61 8 9389 8033
Fax: +61 8 9262 3723

110 Stirling Highway
Nedlands, WA
AU Australia, 6009

Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 09 Jun 2015.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.




Report a bug